With $90 million of pre-orders already on its books, medicinal cannabis company Medical Kiwi is setting up production premises in Christchurch ahead of its longer-term plans for a purpose-built facility at Brightwater in Nelson.
The Nelson-based Kiwi start-up just raised $2 million in two weeks through a PledgeMe crowdfunding campaign towards its bid to be one of the key producers of New Zealand-grown, high-quality medicinal cannabis to service a burgeoning market here and overseas. The company is now looking to raise a further $1 million through a wholesale offer: https://pledgeme.co.nz/investments/413
“We have pre-sold more than our production capacity for our first two years of operation,” says Co-Founder and Chairman Aldo Miccio. “Our supply agreement with Hektares provides us with a solid financial grounding with $30 million worth of medicinal cannabis sales next year and $60 million the following year. We need to get on with delivering on those orders, so we are setting up premises in Christchurch while the design, planning and construction of our Brightwater facility is carried out.”
Miccio says the Christchurch building is already fit for purpose and can comply with the strict New Zealand and international Medicinal Cannabis licensing conditions.
“We will operate solely from this facility until our Nelson site is ready, which won’t be for a few more years,” Miccio says. “When in full production, estimated to be early 2024, our Nelson facility will be designed to produce 30,000 – 35,000 kg of dried product per annum, valued today from $100 – $110 million.”
The investment capital will help grow and produce safe, high-quality, affordable medicinal cannabis and CBD products and ensure they are available to the people who need them the most.
Funds raised through the PledgeMe campaign will be put toward getting the Christchurch premises up and running as soon as possible, marketing, research and the development at Nelson.
“We believe Medical Kiwi will be an attractive investment,” Miccio says. “Our strong point of difference is our blend of science, research and production. We’re committed to an ongoing programme of advanced research and technology to support the development of safe, high-quality medicinal cannabis products.”
To this end, Medical Kiwi has already secured partnerships with cannabis organisations with strong research credentials such as Vitality CBD, Liberty Herbal Technologies, Empirical Labs, and Hektares.
“Our plan is ambitious because we’re striving to be market leaders in this exciting growth industry,” Miccio says. “We will take an innovative, science-based approach to developing and delivering cannabinoid products to those who need them the most. Our robust research, innovative product development, partnerships with global industry-leading companies and agreements for future sales put us in a unique position to create value and carve out a significant share of this emerging industry in New Zealand and globally.”
Medical Kiwi also plans to manufacture its own New Zealand medicinal cannabis products for sale domestically and internationally and has established strong relationships with customers in both of these markets.
“Now all we need are the people who share our excitement at the prospects for this burgeoning industry and are prepared to help us accomplish our objectives by joining our team as investors,” Miccio says.
About Medical Kiwi
Medical Kiwi Limited (Medical Kiwi), an early-stage medicinal research and nutraceutical wellbeing company, is in a unique position as one of a handful of New Zealand companies poised to create value and carve out a significant share of this emerging and exciting growth industry.
The potential of the medicinal and nutraceutical cannabis industry is clearly evidenced in the rapid growth and scale achieved by businesses in Canada and Europe. Globally, the medicinal cannabis industry is forecast to be worth USD $150 billion by 2025*. (*Grand View Research 2018).